Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Viral hepatitis C pandemic: Challenges and threats to its elimination

L. Krekulova, R. Honzák, LW. Riley

. 2021 ; 28 (5) : 694-698. [pub] 20210224

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc22004414

Under the WHO plan, the global elimination of the HCV pandemic is scheduled for 2030. The burden of HCV infection in developed countries is largely borne by people who inject drugs (PWID): new infections and reinfections are related to their risky behaviour. Although safe and sensitive hepatitis C diagnostic tools and directly acting antiviral medication are widely used, major challenges to disease elimination still remain in developed countries, where the WHO plan is in progress. The challenge is in the involvement and engagement of infected PWID. There is a strong need to change our uptake and treatment strategies to address all patients from the risk groups, connect them with the healthcare system and cure them with the vision to eliminate this HCV pandemic.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004414
003      
CZ-PrNML
005      
20220127145254.0
007      
ta
008      
220113s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/jvh.13480 $2 doi
035    __
$a (PubMed)33550694
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Krekulova, Laura $u Remedis s.r.o., Prague, Czech Republic $u 4th Department of Internal Medicine, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
245    10
$a Viral hepatitis C pandemic: Challenges and threats to its elimination / $c L. Krekulova, R. Honzák, LW. Riley
520    9_
$a Under the WHO plan, the global elimination of the HCV pandemic is scheduled for 2030. The burden of HCV infection in developed countries is largely borne by people who inject drugs (PWID): new infections and reinfections are related to their risky behaviour. Although safe and sensitive hepatitis C diagnostic tools and directly acting antiviral medication are widely used, major challenges to disease elimination still remain in developed countries, where the WHO plan is in progress. The challenge is in the involvement and engagement of infected PWID. There is a strong need to change our uptake and treatment strategies to address all patients from the risk groups, connect them with the healthcare system and cure them with the vision to eliminate this HCV pandemic.
650    _2
$a antivirové látky $x terapeutické užití $7 D000998
650    _2
$a Hepacivirus $7 D016174
650    12
$a hepatitida C $x farmakoterapie $x epidemiologie $x prevence a kontrola $7 D006526
650    _2
$a lidé $7 D006801
650    _2
$a pandemie $x prevence a kontrola $7 D058873
650    12
$a intravenózní abúzus drog $x epidemiologie $7 D015819
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Honzák, Radkin $u Remedis s.r.o., Prague, Czech Republic $u Institute of Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Riley, Lee W $u Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, CA, USA
773    0_
$w MED00003046 $t Journal of viral hepatitis $x 1365-2893 $g Roč. 28, č. 5 (2021), s. 694-698
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33550694 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145250 $b ABA008
999    __
$a ok $b bmc $g 1751779 $s 1155563
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 28 $c 5 $d 694-698 $e 20210224 $i 1365-2893 $m Journal of viral hepatitis $n J Viral Hepat $x MED00003046
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Možnosti archivace